Skip to main content

Table 2 Mean changes from baseline in Multidimensional Fatigue Inventory ratings in patients with PGI-I of not more than 2 or greater than 2

From: Improvement in multiple dimensions of fatigue in patients with fibromyalgia treated with duloxetine: secondary analysis of a randomized, placebo-controlled trial

Multidimensional Fatigue Inventory

PGI-I ≤ 2

PGI-I > 2

 

Duloxetine

(n= 114)

Placebo

(n= 64)

Duloxetine

(n= 132)

Placebo

(n= 189)

 

Mean (SE)

Mean (SE)

Mean (SE)

Mean (SE)

General Fatigue

-3.8 (0.4)a

-4.2 (0.5)a

-0.9 (0.3)a

-0.4 (0.2)

Mental Fatigue

-3.1 (0.4)a

-3.1 (0.5)a

-1.1 (0.3)a

-0.5 (0.3)

Physical Fatigue

-3.6 (0.4)a

-3.7 (0.5)a

-0.8 (0.3)a

-0.7 (0.3)a

Reduced Activity

-3.2 (0.4)a

-3.0 (0.5)a

-0.2 (0.3)

0.2 (0.3)

Reduced Motivation

-2.9 (0.4)a

-2.9 (0.5)a

-0.7 (0.3)a

-0.1 (0.3)

  1. aStatistically significant (P ≤ 0.05) within-group change from baseline to endpoint at acute-phase endpoint (week 12). A last-observation-carried-forward analysis was conducted. PGI-I, Patient Global Impression of Improvement; SE, standard error.